-
Developer scraps treatment for 2 MD types after disappointing trial results
Drug maker Servier announced that it is discontinuing development of its oral treatment candidate sevasemten for both Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). The announcement comes just days after top-line data, or the first results of a clinical trial, showed that sevasemten had failed to hit the main goal or key secondary goals…
-
PPMD Announces Levine Children’s Hospital as Certified Duchenne Care Center, Marking 40th Center in Growing Network
PPMD is excited to announce the expansion of its renowned Certified Duchenne Care Center (CDCC) Program with the certification of the clinic at Atrium Health Levine Children’s Hospital in Charlotte, North Carolina. The certification marks the 40th center in PPMD’s growing CDCC network, an important milestone in PPMD’s ongoing commitment to making comprehensive, coordinated, and…








